1. Home
  2. BBU vs ADPT Comparison

BBU vs ADPT Comparison

Compare BBU & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Business Partners L.P. Limited Partnership Units

BBU

Brookfield Business Partners L.P. Limited Partnership Units

HOLD

Current Price

$31.46

Market Cap

3.1B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.11

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBU
ADPT
Founded
2016
2009
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.3B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
BBU
ADPT
Price
$31.46
$14.11
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$39.40
$17.78
AVG Volume (30 Days)
48.7K
1.9M
Earning Date
05-01-2026
05-05-2026
Dividend Yield
0.79%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
N/A
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$19.91
$6.77
52 Week High
$37.75
$20.76

Technical Indicators

Market Signals
Indicator
BBU
ADPT
Relative Strength Index (RSI) 44.87 49.46
Support Level $29.90 $12.19
Resistance Level $36.93 $17.72
Average True Range (ATR) 1.38 0.98
MACD 0.23 0.14
Stochastic Oscillator 46.92 58.46

Price Performance

Historical Comparison
BBU
ADPT

About BBU Brookfield Business Partners L.P. Limited Partnership Units

Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: